Kyowa Kirin Co., Ltd.
4151
Ранг среди акций
#2443
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Цена акции
$15.32
Рыночная капитализация
$8.02B
Изменение (1 день)
0.88%
Изменение (1 год)
2.20%
Страна
JP
Торговля Kyowa Kirin Co., Ltd. (4151)
Категория
Healthcare
Прибыль Kyowa Kirin Co., Ltd. (4151)
Прибыль на Jun 2026 TTM: $670.11M
Согласно последним финансовым отчетам Kyowa Kirin Co., Ltd., текущая прибыль компании составляет $670.11M. В 2024 году компания получила прибыль $531.54M, меньше, чем прибыли за 2023, которая составила $689.55M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Kyowa Kirin Co., Ltd. с 2001 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $670.11M | 20.53% |
| 2025 | $555.99M | 4.60% |
| 2024 | $531.54M | -22.92% |
| 2023 | $689.55M | 33.80% |
| 2022 | $515.37M | -1.21% |
| 2021 | $521.68M | 3.05% |
| 2020 | $506.23M | 23.66% |
| 2019 | $409.36M | -38.89% |
| 2018 | $669.84M | 35.13% |
| 2017 | $495.69M | 91.40% |
| 2016 | $258.98M | -24.70% |
| 2015 | $343.93M | 51.18% |
| 2014 | $227.50M | -51.87% |
| 2013 | $472.68M | -9.21% |
| 2012 | $520.61M | -13.00% |
| 2011 | $598.40M | 14.88% |
| 2010 | $520.91M | 134.43% |
| 2009 | $222.20M | -42.92% |
| 2008 | $389.26M | 95.19% |
| 2007 | $199.42M | -5.68% |
| 2006 | $211.43M | -24.31% |
| 2005 | $279.35M | 89.18% |
| 2004 | $147.66M | 2.74% |
| 2003 | $143.72M | 52.82% |
| 2002 | $94.04M | -46.07% |
| 2001 | $174.37M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| $33.60B | 4,913.43% |
US
|
|
| $17.74B | 2,546.87% |
US
|
|
| $8.70B | 1,198.14% |
US
|
|
| $5.95B | 787.61% |
US
|
|
| $21.39B | 3,091.75% |
CH
|
